RTP Mobile Logo

Thursday, May 17, 2018, Washington, DC, 6:00 PM – 8:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A CNE Symposia Series Held During the 43rd Annual ONS Congress

PART 4 — Non-Small Cell Lung Cancer

Event Details

Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
5:30 PM – 6:00 PM
Registration and Dinner Buffet

6:00 PM – 8:30 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Julie R Brahmer, MD
Director, Thoracic Oncology Program
Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, Maryland

Jennifer Kapo, MD
Chief, Palliative Care Service
Yale New Haven Hospital
Associate Professor of Medicine
Department of Internal Medicine
Yale University School of Medicine
New Haven, Connecticut

Judy Pagtama, RN, MSN, FNP-C
Nurse Practitioner
Stanford Cancer Institute
Palo Alto, California

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Elizabeth S Waxman, RN, MSN, ANP-BC
Nurse Practitioner in the Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Merck and Takeda Oncology during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Module 1: Optimal Tumor Testing Algorithms; Management of Non-Small Cell Lung Cancer (NSCLC) with EGFR-Activating Mutations


  • Incidence of lung cancer driver mutations and indications for mutational analysis
  • Recent FDA approval of osimertinib as first-line therapy; selection of up-front EGFR tyrosine kinase inhibitor (TKI)
  • Comparative toxicities and management of side effects associated with the approved EGFR TKIs
  • Mechanisms of resistance in patients with disease progression on first-line EGFR TKI therapy; choice of second-line treatment after progression on osimertinib
  • Activity of EGFR TKIs in patients with CNS metastases
  • Sequencing immune checkpoint inhibitors for patients with metastatic NSCLC and tumor mutations

Module 2: Existing and Emerging Therapeutic Options for Patients with ALK- and ROS1-Positive Disease


  • Efficacy of crizotinib in patients with ALK and ROS1 rearrangements; unique associated toxicities
  • Available data and FDA approvals of alectinib and ceritinib as first-line therapy for ALK-positive disease
  • Integrating the recently FDA-approved ALK inhibitor brigatinib into the treatment algorithm
  • Tolerability issues and dosing considerations with next-generation ALK inhibitors
  • Variable CNS permeability with approved and investigational ALK inhibitors and implications for patients with ALK-positive brain metastases

Module 3: Other Potentially Targetable Tumor Mutations (BRAF V600E, HER2, RET, et cetera)


  • Current role of BRAF inhibitor therapy, with or without a MEK inhibitor, for BRAF V600E mutation-positive NSCLC
  • Tolerability profile of combined BRAF/MEK inhibition
  • Incidence of HER2 mutations and available data with HER2-targeted agents in NSCLC
  • Preliminary efficacy and safety data with investigational targeted agents for RET-rearranged NSCLC
  • Clinical significance of MET exon 14 skipping mutations and current role of crizotinib

Module 4: Practical Integration of Anti-PD-1/PD-L1 Antibodies into Current Treatment Algorithms for Patients with Locally Advanced NSCLC


  • Potential synergy between radiation therapy and immune checkpoint inhibitors
  • Recent FDA approval of durvalumab and major efficacy and safety findings from the PACIFIC trial; role of sequential durvalumab in the management of Stage III disease
  • Impact of radiation therapy-induced side effects on the decision to administer an immune checkpoint inhibitor
  • Active and planned studies of other immune checkpoint inhibitors as consolidation treatment after chemoradiation therapy for locally advanced disease

Module 5: Clinical Approach to Metastatic NSCLC without a Targetable Mutation


  • PD-L1 tumor proportion score as a predictor of response to immune checkpoint inhibitor therapy
  • FDA approval of pembrolizumab in combination with carboplatin/pemetrexed as first-line therapy for metastatic nonsquamous NSCLC; patient selection for and administration of this approach in clinical practice
  • Design, eligibility criteria and major safety and efficacy findings from the Phase III IMpower150 study evaluating atezolizumab and bevacizumab in combination with carboplatin/paclitaxel for previously untreated advanced nonsquamous NSCLC
  • Available data with and current clinical role of anti-PD-1/PD-L1 antibodies as second-line therapy
  • Available safety and efficacy data with combinations of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies in metastatic NSCLC
  • Monitoring and amelioration of immune-related adverse events in patients receiving checkpoint inhibitors

Special Session: Dr Kapo

Using effective palliative care strategies to improve survival and other outcomes for patients with cancer

CE Information

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer (NSCLC).

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Appreciate available research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with locally advanced, unresectable NSCLC.
  • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
  • Discuss the benefits and risks associated with evidence-based systemic treatments for metastatic NSCLC, including chemotherapeutic agents, targeted biologic therapies and immunotherapies.
  • Educate patients about the side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Assess emerging research on the benefits of early palliative care for patients with metastatic NSCLC, and integrate this information, as appropriate, into patient consultations.
  • Recall ongoing trials of other investigational approaches and agents in NSCLC, and refer patients and obtain consent for study participation.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 2.5 contact hours is provided by RTP.

This activity is awarded 2.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2018/ILNA

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP staff and external reviewers — The scientific staff, planners and managers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Merck and Takeda Oncology.


Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room: 
Independence A-E (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and provides direct access to the Walter E Washington Convention Center via an underground concourse.



Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 4 — Non Small Cell Lung Cancer. Onsite registration will be open starting at 5:15 PM (ET) on Thursday, May 17th.

If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside Independence A-E, Ballroom (Meeting Level 4) at the Marriott Marquis Washington, DC (901 Massachusetts Ave NW, Washington, DC 20001). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.